A
Anny-Yue Yin
Publications - 3
Citations - 336
Anny-Yue Yin is an academic researcher. The author has contributed to research in topics: Erlotinib & Hazard ratio. The author has an hindex of 3, co-authored 3 publications receiving 255 citations.
Papers
More filters
Journal ArticleDOI
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Xiaoqing Liu,Yunzhong Zhu,Shun Lu,Jifeng Feng,Jianxing He,Baohui Han,Jie Wang,Guo-Liang Jiang,Chunhong Hu,Hao Zhang,Gang Cheng,Xiangqun Song,You Lu,Hongming Pan,Wenjuan Zheng,Anny-Yue Yin +18 more
TL;DR: The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC.
Journal ArticleDOI
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies
Yi-Long Wu,Victor C. S. Lee,Victor C. S. Lee,Chong-Kin Liam,Shun Lu,Keunchil Park,Vichien Srimuninnimit,Jie Wang,Caicun Zhou,Anita Appius,Peter Button,Gregory Hooper,John F. Palma,Katja Schulze,Sidney A Scudder,David S. Shames,Anny-Yue Yin,Guili Zhang,Tony Mok +18 more
TL;DR: Blood-based EGFR mutation testing demonstrated high specificity and good sensitivity, and offers a convenient and easily accessible diagnostic method to complement tissue-based tests.
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer Whose Tumors Harbor Uncommon Epidermal Growth Factor Receptors Mutations
Barbara Klughammer,Wolfram Brugger,Federico Cappuzzo,Tudor Ciuleanu,Tony Mok,Martin Reck,Eng Huat Tan,Paul Delmar,Gaelle Klingelschmitt,Anny-Yue Yin,Olivia Spleiss,Lin Wu,David S. Shames +12 more